Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPY4R | P50391 | 6/20 | 0.32 |
| ▸ | NPY1R | P25929 | 4/20 | 0.32 |
| ▸ | NPY2R | P49146 | 2/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404058 | 1.00 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL30158908 | 0.98 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| Trifluoroacetic Acid SCHEMBL10871348 | 0.85 | NPY4R (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL20822004 | 0.83 | MEN1 (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL171399 | 0.82 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL7158448 | 0.82 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL11535264 | 0.82 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL6545308 | 0.82 | ALOX15 (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL18822222 | 0.82 | MEN1 (0.40) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL5147807 | 0.80 | MEN1 (0.45) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4604984-A1 | INHIBITORS | Zealand Pharma A/S (DK) | 2025-08-27 | — | — | EP | claimed |
| WO-2024083919-A1 | INHIBITORS | ZEALAND PHARMA A/S (DK) | 2024-04-25 | — | — | WO | claimed |
| US-20240076328-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2024-03-07 | — | — | US | claimed |
| US-11780893-B2 | Kv1.3 blockers | ZEALAND PHARMA A/S (DK) | 2023-10-10 | — | — | US | claimed |
| US-20220251151-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2022-08-11 | — | — | US | claimed |
| EP-4604984-A1 | INHIBITORS | Zealand Pharma A/S (DK) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024083919-A1 | INHIBITORS | ZEALAND PHARMA A/S (DK) | 2024-04-25 | — | — | WO | disclosed |
| US-20240076328-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2024-03-07 | — | — | US | disclosed |
| US-11780893-B2 | Kv1.3 blockers | ZEALAND PHARMA A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20220251151-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2022-08-11 | — | — | US | disclosed |
| CN-114728039-A | Kv1.3 blocking agents | 西兰制药公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11292820-B2 | KV1.3 blockers | ZEALAND PHARMA A/S (DK) | 2022-04-05 | — | — | US | disclosed |
| US-20210380646-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2021-12-09 | — | — | US | disclosed |
| WO-2021053194-A1 | KV1.3 BLOCKERS | ZEALAND PHARMA A/S (DK) | 2021-03-25 | — | — | WO | disclosed |
| US-6696500-B2 | BIOACTIVE SUBSTANCE HAVING ACIDIC GROUP AND A BIODEGRADABLE POLYMER HAVING AN OPTIONALLY PROTECTED BASIC GROUP, SUCH AS A POLYLACTONE THAT HAS BEEN ESTERIFIED, AMIDATED, OR THIOESTERIFIED WITH A COMPOUND HAVING CYCLIC AMINO GROUPS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-0815853-B1 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20010038854-A1 | Sustained-release preparation | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6264970-B1 | BIODEGRADABLE POLYMER | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-24 | — | — | US | disclosed |
| EP-0815853-A2 | Sustained-release preparation for bioactive substance having an acidic group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780893-B2 | Kv1.3 blockers | KCNA3, KCNK3, KCNN3 | MEN1 3394/4885CYP1A2 4830/4885KMT2A 644/4885 |
| US-20010038854-A1 | Sustained-release preparation | BMP2, PGF, AREG | MEN1 3623/4885CYP1A2 4062/4885KMT2A 4788/4885 |
| US-11292820-B2 | KV1.3 blockers | KCNA3, KCNK3, KCNN3 | MEN1 3394/4885CYP1A2 4830/4885KMT2A 644/4885 |
| US-20240076328-A1 | KV1.3 BLOCKERS | KCNA3, KCNK3, KCNN3 | MEN1 3394/4885CYP1A2 4830/4885KMT2A 644/4885 |
| US-20210380646-A1 | KV1.3 BLOCKERS | KCNA3, KCNK3, KCNN3 | MEN1 3394/4885CYP1A2 4830/4885KMT2A 644/4885 |
| US-20220251151-A1 | KV1.3 BLOCKERS | KCNA3, KCNK3, KCNN3 | MEN1 3394/4885CYP1A2 4830/4885KMT2A 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.